ICU Medical Reports Q4 2025 Results and Issues Positive FY 2026 GAAP Net Income Guidance

summarizeSummary

ICU Medical reported Q4 2025 results with revenue decline but improved GAAP net loss, and issued FY 2026 guidance forecasting positive GAAP net income and adjusted EPS.

check_boxKey Events

• Q4 2025 Revenue Performance

  Reported $540.7 million in revenue for Q4 2025, a 14% decrease compared to $629.8 million in Q4 2024, primarily attributed to the divestiture of the IV Solutions business. Organic revenue, however, grew by 2%.

• Q4 2025 Profitability Metrics

  GAAP net loss improved to $(15.7) million, or $(0.64) per diluted share, from $(23.8) million in the prior year. Adjusted diluted EPS decreased to $1.91 from $2.11 in Q4 2024.

• Fiscal Year 2026 Guidance Issued

  The company provided FY 2026 guidance, projecting GAAP net income between $26 million and $44 million, and adjusted EPS in the range of $7.75 to $8.45, indicating an expected return to GAAP profitability.

auto_awesomeAnalysis

ICU Medical, Inc. announced mixed fourth-quarter 2025 results, with a significant year-over-year revenue decline primarily due to the divestiture of its IV Solutions business, though organic revenue growth was positive. Despite a GAAP net loss for the quarter, the company provided full-year 2026 guidance projecting a return to GAAP net income and positive adjusted EPS, signaling an anticipated improvement in profitability. Investors will focus on the company's ability to execute on its 2026 guidance and continue driving organic growth following the portfolio adjustments.